Effect of the Principle of Activating Blood Circulation to Break Stasis on GMP-140 and D_2 Dimer in Patients with Acute Cerebral Infarction

Objective: To explore the clinical efficacy of the principle of activating blood circulation to break stasis (ABCBS) and its influence on platelet membranous protein particle (GMP-140) and D 2 dimer (D-dimer) before and after treatment. Methods: Eighty-eight patients with blood stasis syndrome (BSS) of acute cerebral infarction (ACI) were randomly divided into two groups, both of which were treated with conventional treatment, i.e. with western medicine (WM), with Salvia injection added through intravenously dripping.One of the two groups was used as the control and the other group as the treated group who had ABCBS herbs orally taken in addition. The duration of treatment course for both groups was 3 weeks. Results: There were changes in both groups over clinical symptoms, nerve function deficit scoring and GMP-140, D-dimer, but the treated group showed significantly better than that of the control group, ( P <0.05). Conclusion: ABCBS principle could serve as an important auxiliary treating method for BSS of ACI, as it can effectively alter the blood of ACI patients which was viscous, condense, coagulant and aggregating.

Efficacy and mechanism of Xiaoshuan enteric-coated capsule as an adjunctive treatment for ischemic stroke:A randomized clinical trial

Objective:To explore the clinical efficacy of Xiaoshuan enteric-coated capsule(XSECC)in treating ce-rebral infarction and its potential mechanism of action.Methods:Patients with acute ischemic stroke(AIS)of the qi deficiency and blood stasis type were randomly assigned to the control and observation groups.They were evaluated using the National In-stitutes of Health Stroke Scale(NIHSS),Activities of Daily Living(ADL),Hachinskilnchemic Scale(HIS),Barthel Index(BI),clinical efficacy scores,and TCM syndrome scores on days 0,14,30,and 90.Furthermore,VEGF and BDNF levels were measured on days 30 and 90.Finally,we analyzed the changes in each scale score and vascular neurological factor in both groups.Results:After 14 days of treatment,the difference values in NIHSS,ADL,and BI were higher,and TCM syndrome and clinical efficacy scores were increased in the observation group compared with those of the control group(all P<0.05).After 30 days,the NIHSS,ADL,HIS,and TCM syndrome scores were decreased compared with those of the control group,while BI and clinical efficacy scores were increased(all P<0.05).After 90 days,the difference value in ADL was higher,and TCM syndrome score was increased in the observation group compared with that of the control group(P=0.047,P=0.005,respectively).The levels of VEGF and BDNF were higher in the observation group than in the control group on days 14,30,and 90(all P<0.05).VEGF and BDNF levels on day 0 were associated with prognosis of patients with AIS;therefore,they have a predictive value for the prognosis of acute cerebral infarction.Conclusions:XSECC therapy can improve clinical outcomes in patients with acute and recurrent cerebral infarctions.Its mechanism of action may be associated with the secretion of VEGF and BDNF.

Apolipoprotein E polymorphisms increase the risk of post-stroke depression

Recent reports have shown that apolipoprotein E （APOE） polymorphisms are involved in neurodegenerative disease. However, it is unclear whether APOE affects post-stroke depression. Accordingly, we hypothesized that APOE polymorphisms modify the risk of post-stroke depression. Here, we performed a hospital-based case-control study （including 76 cerebral infarction cases with post-stroke depression, 88 cerebral infarction cases without post-stroke depression, and 109 controls without any evidence of post-stroke depression or cerebral infarction） to determine possible association between APOE rs429358 and rs7412 polymorphisms and risk of post-stroke depression. Our findings show no difference among the groups with regards genotype distribution of the rs7412 polymorphism. In contrast, APOE genotypes with rs429358-C alleles increased the risk of post-stroke depression. Further, the rs429358 polymorphism was associated with significantly decreased regional cerebral blood flow values in the left temporal lobe of post-stroke depression cases. Additionally, the rs429358 polymorphism was not only associated with depression severity, but with increasing serum levels of total cholesterol. These resuits suggest that the APOE rs429358 polymorphism is associated with increased risk of developing post-stroke depression, and that APOE rs429358-C allele genotypes may be detrimental to recovery of nerve function after stoke. Indeed, these findings provide clinical data for future post-stroke depression gene interventions.

Research Progress on the Pharmacological Mechanisms of Chinese Medicines that Tonify Qi and Activate Blood Against Cerebral Ischemia/Reperfusion Injury

Cerebral ischemia-reperfusion injury(CIRI) refers to a pathological phenomenon that aggravates the injury after the restoration of blood perfusion and oxygen supply to the cerebral ischemia-induced tissues and organs, with a relatively high incidence. The traditional Chinese medicine(TCM) believes that Qi deficiency and blood stasis are the cause of CIRI. Therefore, Chinese medicine for tonifying Qi and activating blood is regarded as an important choice for the treatment of CIRI. In recent years, it has been found that many Chinese herbal medical ingredients and compound Chinese medicine(CCM) have significant anti-CIRI effects, and their mechanisms of action mainly include improving brain blood supply, neuroprotection, regulating signal pathways such as TLR4/HO-1/Bcl-2, protecting mitochondrial function, regulating related protein levels, and regulating oxidative molecule levels. This article summarizes and introduces the pharmacological mechanisms of Tonifying-Qi and activating-blood Chinese medicine and CCM which have the function of anti-CIRI. Our goal is to provide effective reference for further researches on the cerebral protection of related TCMs or compounds and their clinical application.

补阳还五汤治疗脑梗死恢复期患者的临床疗效

目的:探究补阳还五汤治疗脑梗死恢复期患者的临床疗效。方法:按照治疗药物不同将84例气虚血瘀型脑梗死恢复期患者分为中药组和常规组,每组各42例。常规组采用常规药物治疗;中药组联合补阳还五汤辅助治疗。比较两组治疗前、治疗4周后的中医症候积分、神经功能、认知功能、肢体运动能力。结果:治疗4周后,两组患者中医症候积分各维度及总分、血清超敏C反应蛋白(hs-CRP)、血栓调节蛋白(TM)水平均低于治疗前,且中药组低于常规组(P<0.05);两组患者血清脱氢表雄酮(DHEA)、脑源性神经营养因子(BDNF)水平、蒙特利尔认知评估量表(MoCA)评分、Fugl-Meyer运动功能评分(FMA)均较治疗前升高(P<0.05),且中药组高于常规组(P<0.05);血清VEGF水平较治疗前降低(P<0.05),但中药组高于常规组(P<0.05)。结论:补阳还五汤可有效改善脑梗死恢复期患者临床症状,提高DHEA、BDNF水平和认知功能,促进肢体运动恢复。

Diagnostic value of traditional Chinese medical dialectical classification in hashimoto's thyroiditis complicated with suspicious nodules

Objective:To explore the diagnostic value of traditional Chinese medical(TCM)dialectical classification in Hashimoto's thyroiditis complicated with suspicious nodules.Methods:The clinical data of patients with Hashimoto's thyroiditis complicated with thyroid nodules in the Department of Breast and thyroid surgery of Weifang Hospital of traditional Chinese Medicine from January 2018 to December 2019 were collected.The patients were examined by 2 or more experienced TCM doctors,and the four diagnostic data were obtained,and then the relevant syndrome types of the patients were judged according to the data.According to the color Doppler ultrasonographic features of thyroid nodules,the patients who met the indication of fine needle aspiration biopsy of thyroid nodules were selected and underwent fine needle aspiration biopsy of thyroid nodules before operation.To analyze the clinical diagnostic value of that the ultrasonic mode used in this study and thyroid cytopathology Bethesda report system combine dialectical classification of traditional Chinese medicine in Hashimoto's thyroiditis complicated with suspected thyroid nodules.Result:A total of 89 patients with Hashimoto's thyroiditis complicated with thyroid nodules were collected.according to the ultrasonic mode,the difference between different modes was statistically significant(P<0.05).The mode of color ultrasound is also related to the dialectical classification of traditional Chinese medicine.The patients with high malignant risk score are mainly qi depression and phlegm stagnation,phlegm and blood stasis,while those with low score are exuberant liver fire and heart liver yin deficiency.According to the study of different The Bethesda System for Reporting Thyroid Cytopathology(TBSRTC)classification,the dialectical classification of patients with higher TBSRTC classification was more inclined to qi depression and phlegm stagnation,phlegm and blood stasis,and there was significant difference between different classification(P<0.05).Conclusion:Qi depression and phlegm obstruction,phlegm and blood stasis have high ultrasound malignant risk score and high TBSRTC classification grade in patients with Hashimoto's thyroiditis complicated with suspected thyroid nodules,which has important clinical diagnostic value.

炙黄芪-水蛭联合阿加曲班注射液治疗气虚血瘀型急性脑梗死的疗效观察

[目的]探究炙黄芪-水蛭联合阿加曲班注射液治疗气虚血瘀型急性脑梗死的疗效观察。[方法]选取2021年2月—2023年2月于本院进行急性脑梗死治疗的患者110例,按照随机数字表法将其分为阿加曲班注射液组(西药组)34例、炙黄芪-水蛭组(中药组)36例,以及联合组40例。西药组给予阿加曲班注射液;中药组给予炙黄芪-水蛭;联合组给予炙黄芪-水蛭联合阿加曲班注射液治疗。评估患者治疗前后中医证候积分水平;采用美国国立卫生研究院卒中量表(NIHSS)、改良Rankin(mRS)评分量表评估患者自身的神经功能缺损情况以及神经功能恢复情况;检测脑血流阻力指数(RI)、舒张期血流速度(Vd)、收缩期峰值流速(Vs)、平均血流速度(Vm)、血管内皮生长因子(VEGF)、一氧化氮(NO)水平。[结果]治疗后,联合组中医证候积分、NIHSS、mRS评分、RI、VEGF水平均低于西药组、中药组(P<0.05);Vd、Vs、Vm、NO水平高于西药组、中药组(P<0.05);联合组总有效率较高(P<0.01)。[结论]经炙黄芪-水蛭、阿加曲班注射液联合治疗,其气虚血瘀型急性脑梗死患者中医证候积分水平降低,相关神经功能、血流情况及血管内皮损伤情况均得到显著改善,临床治疗效果显著。

从“金郁泄之”论治溃疡性结肠炎

“金郁泄之”理论出自《黄帝内经》,“金”是肺与肠的基本属性,“郁”指郁滞,壅塞不通的异常状态,故“金郁”可理解为属金脏腑如肺、大肠所发壅滞、阻塞之证。“泄之”是五行属金脏腑郁滞的治疗方法,其具体含义应随“金郁”的病理产物、病位的不同而不同。溃疡性结肠炎多由邪蕴肠腑,气血瘀滞,肠道传导失司,湿、热、瘀于大肠相互搏结成郁,改变肠道属金肃降之性所致,其核心病机为湿热内蕴,气血瘀滞,属于“金郁”的范畴,病位虽在大肠,可波及于肺。故治疗应顺应“泄之”的法则,以祛除肺肠之郁为主,包括清泄与宣泄两种方法,同时补益肺、脾、肾三脏之气,以恢复肺肠之功能,达到扶正祛邪,标本兼顾的目的,促进溃疡性结肠炎的愈合。

通调针刺法联合康复疗法治疗气虚血瘀型脑梗死后运动障碍临床观察

目的评估通调针刺法联合康复疗法治疗气虚血瘀型脑梗死后运动障碍的临床疗效。方法将60例气虚血瘀型脑梗死后运动障碍患者随机分为对照组和治疗组,每组30例。两组患者均给予基础治疗,对照组患者给予康复治疗,治疗组患者给予康复治疗联合通调针刺法治疗,两组疗程均为4周。比较治疗前后两组患者简化Fugl-Meyer评估(Fugl-Meyer assessment,FMA)量表评分和日常生活活动能力(activity of daily living,ADL)量表评分、气虚血瘀证证候积分、血清转铁蛋白(transferrin,TF)和神经生长因子(nerve growth factor,NGF)水平,对比两组总体疗效。结果治疗组脱落2例患者,对照组脱落1例患者。与治疗前比较,两组患者治疗后FMA量表评分和ADL量表评分均显著上升(P<0.05),气虚血瘀证证候积分显著降低(P<0.05),血清TF和NGF水平显著升高(P<0.05),且治疗组FMA量表评分和ADL量表评分及血清TF和NGF水平升高程度、气虚血瘀证证候积分降低程度均显著大于对照组(P<0.05)。治疗组临床疗效显著优于对照组(P<0.05)。结论通调针刺法联合康复疗法治疗气虚血瘀型脑梗死后运动障碍疗效显著。

宫颈高危型人乳头瘤病毒感染患者中医体质类型分布研究

目的:分析宫颈高危型人乳头瘤病毒(high risk human papilloma virus,HR-HPV)感染患者中医体质类型分布特点,为中医药调理体质防治宫颈HR-HPV感染提供依据。方法:选择2019年1月至2020年12月就诊于河南中医药大学第一附属医院妇科门诊及体检中心的420例宫颈HR-HPV感染者作为观察组,选择420例同时段宫颈HR-HPV检测阴性者为对照组。分析两组中医体质类型分布情况、观察组不同年龄段中医体质类型分布情况、观察组不同HR-HPV基因型别中医体质类型。结果:观察组中医体质分布依次为:痰湿质(30.50%)>湿热质(19.00%)>平和质(15.50%)>阳虚质(14.80%)>气虚质(10.00%)>阴虚质(5.90%)>瘀血质(2.70%)>气郁质(1.70%);对照组中医体质分布依次为:平和质(73.30%)>湿热质(8.40%)>阴虚质(5.70%)>痰湿质(4.50%)>气虚质(4.30%)>阳虚质/瘀血质(1.80%)>气郁质(0.20%)。两组中医体质类型比较,差异具有统计学意义(P<0.05),其中,痰湿质、湿热质、阳虚质、气虚质,两组间比较,差异具有统计学意义(P<0.001)。观察组体质类型居前三位的是痰湿质、湿热质、阳虚质,占全部体质类型的64.30%。对照组平和质324例,占比73.50%,观察组平和质81例,占比15.50%,两组间比较,差异具有统计学意义(P<0.001)。观察组中,痰湿质、阳虚质、阴虚质主要见于46~55岁,湿热质、气虚质、气郁质主要见于36~45岁,组间比较差异具有统计学意义(P<0.05)。两组宫颈HR-HPV16、18型和非16、18型中医体质比较,差异无统计学意义(P>0.05)。结论:痰湿质、湿热质、阳虚质为宫颈HR-HPV感染人群的易感体质;痰湿质、湿热质、阳虚质与年龄具有相关性,痰湿质多见于36~45岁,湿热质、阳虚质多见于46~55岁,HR-HPV基因型别与中医体质类型之间无明显相关性。

加味补阳还五汤联合镜像疗法对气虚血瘀型脑梗死后中重度上肢偏瘫患者脑侧支循环建立及肢体康复的影响分析

目的探究加味补阳还五汤联合镜像疗法对气虚血瘀型脑梗死后中重度上肢偏瘫患者脑侧支循环建立及肢体康复的影响分析。方法选取气虚血瘀型脑梗死后中重度上肢偏瘫患者100例,随机分为两组,每组50例。对照组使用常规治疗,观察组在对照组基础上联合加味补阳还五汤及镜像疗法治疗,疗程为4周,对比两组患者临床治疗效果、美国国会卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)评分、蒙特利尔认知评估量表(Montreal Cogni-tive Assessmen,MoCA)、基质细胞源性因子1(Stromal cell-derived factor 1,SDF1)、S100钙结合蛋白B(S100 calcium bind-ing proteinB,S100B)、血小板源性生长因子(Platelet-derived growth factor,PDGF)、福格-米勒运动功能评分量表(Fugl-Meyer motor function assessment,FMA)评分及巴塞尔指数(Barthel index,BI)评分。结果治疗后对照组总有效率为68.00%(34/50),显著低于观察组的90.00%(45/50)(P<0.05);治疗后两组NIHSS评分较治疗前显著降低(P<0.05),观察组评分显著低于对照组(P<0.05);治疗后两组MoCA评分均较治疗前提高(P<0.05),观察组评分显著高于对照组(P<0.05);治疗后两组PDG水平均显著升高,观察组显著高于对照组(P<0.05);SDF-1、S100B水平均显著降低,且观察组显著低于对照组(P<0.05);治疗后两组FMA评分及BI评分均较治疗前显著提升(P<0.05),观察组显著高于对照组(P<0.05)。结论加味补阳还五汤联合镜像疗法治疗气虚血瘀型脑梗死后中重度上肢偏瘫患者具有良好的临床治疗效果,显著改善患者神经功能及认知水平,促进脑血管新生和侧支循环形成,并改善患者肢体运动功能,全面提升患者生存质量。

益肾通脉膏方对脉络膜前动脉区脑梗死(肾虚血瘀痰阻证)神经功能恢复的疗效及血清脑源性神经营养因子的影响

目的探讨益肾通脉膏方在肾虚血瘀痰阻证脉络膜前动脉(anterior choroidal artery,AchA)区脑梗死患者中的应用效果。方法选取2021年12月—2023年9月泰安市中医医院收治的80例肾虚血瘀痰阻证AchA区脑梗死患者为研究对象,以治疗方法的不同分为两组,各40例。对照组行阿司匹林肠溶片治疗,观察组在对照组基础上增加益肾通脉膏方治疗。对比两组临床疗效、神经功能、日常生活能力、血清脑源性神经营养因子(brain derived neurotrophic factor,BDNF)水平及不良反应发生情况。结果观察组治疗总有效率为92.50%(37/40),高于对照组的75.00%(30/40),差异有统计学意义(χ^(2)=4.501,P<0.05)。治疗前,两组美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分、Barthel指数(Barthel Index,BI)、改良Rankin量表(Modified Rankin Scale,mRS)评分、BDNF水平比较,差异无统计学意义(P均>0.05)。治疗后,观察组NIHSS评分、mRS评分、BI、BDNF水平均优于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论益肾通脉膏方能够减轻肾血瘀痰阻证AchA区脑梗死患者的神经功能损伤,提升日常生活能力,调节血清BDNF水平,且无严重不良反应。

益气通脉汤联合针刺治疗气虚血瘀型急性脑梗死临床观察

目的探讨益气通脉汤联合针刺疗法对气虚血瘀型急性脑梗死患者血液流变学及血清相关指标的影响。方法将2021年6月—2022年6月泉州市中医院内科收治的气虚血瘀型急性脑梗死患者80例作为观察对象,按随机数字表法分成对照组(40例)、研究组(40例)。两组均行常规西医治疗,研究组同时采用益气通脉汤联合针刺治疗,对比两组治疗前后血液流变学、血清相关指标水平和不良反应发生率。结果与治疗前相比,治疗2周后,两组纤维蛋白原、高切血黏度、D-二聚体、血浆黏度及血清低氧诱导因子-1α(HIF-1α)水平均下降,且研究组较对照组更低,两组血清血管内皮生长因子(VEGF)水平均升高,且研究组较对照组更高,差异有统计学意义(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论气虚血瘀型急性脑梗死患者接受益气通脉汤联合针刺治疗能更好地调控血液流变学指标和血清相关指标,改善脑血液循环,加快病情恢复,且安全性高。

半夏白术天麻汤加减联合康复训练治疗风痰瘀阻型急性脑梗死合并H型高血压临床研究

目的:观察半夏白术天麻汤加减联合康复训练对风痰瘀阻型急性脑梗死合并H型高血压患者神经功能及生活质量的影响。方法:将182例风痰瘀血型急性脑梗死合并H型高血压患者按照随机数字表法分为对照组和观察组,每组各91例。两组均接受西医基础治疗,对照组给予康复训练治疗,观察组在对照组治疗的基础上联合半夏白术天麻汤加减。比较两组患者的临床疗效及治疗前后中医证候积分、美国国立卫生研究院卒中量表(national institutes of health stroke scale,NIHSS)评分、世界卫生组织生活质量评定简表(world health organization quality of life-bref,WHOQOL-BREF)评分、收缩压(systolic blood pressure,SBP)、舒张压(diastolic blood pressure,DBP)、同型半胱氨酸(homocysteine,Hcy)水平变化情况。结果:观察组有效率为94.51%,明显高于对照组的75.82%,差异具有统计学意义(P<0.05)。两组患者治疗后中医证候积分、NIHSS评分低于本组治疗前,WHOQOL-BREF评分高于本组治疗前,且治疗后组间比较,差异具有统计学意义(P<0.05)。两组患者治疗后HCY、SBP、DBP水平低于本组治疗前,且观察组治疗后低于对照组(P<0.05)。结论:半夏白术天麻汤加减结合康复训练治疗风痰瘀阻型急性脑梗死合并H型高血压,临床疗效确切,可促进患者神经功能的恢复,提高患者的生活质量。

涤痰汤合桃红四物汤加减治疗痰瘀阻络型脑梗死恢复早期临床观察

目的:观察涤痰汤合桃红四物汤加减治疗痰瘀阻络型脑梗死恢复早期的临床疗效。方法:选取符合纳入标准的痰瘀阻络型脑梗死恢复早期患者96例,采用随机数字表法分为两组各48例。对照组予常规对症治疗及个体化康复综合训练,治疗组在对照组基础上予涤痰汤合桃红四物汤加减治疗。比较两组神经功能缺损程度、中医证候积分、神经损伤因子水平、脑血流动力学指标水平。结果:治疗后,两组卒中量表(NIHSS)评分、中医证候积分、各项神经损伤因子水平、各项脑血流动力学指标水平均较治疗前改善(P﹤0.05),且治疗组改善幅度均优于对照组(P﹤0.05)。结论:涤痰汤合桃红四物汤加减对痰瘀阻络型脑梗死恢复早期脑神经的保护作用较好,可有效改善脑血流动力学。

化瘀通脉汤联合rt-PA静脉溶栓治疗气虚血瘀证脑卒中临床观察

目的:探讨化瘀通脉汤联合rt-PA静脉溶栓治疗气虚血瘀证脑卒中的临床效果。方法:回顾性选取2020年9月~2023年9月聊城市人民医院收治的100例气虚血瘀证脑卒中患者为研究对象,根据治疗方法分为研究组61例及对照组39例。研究组采用化瘀通脉汤联合rt-PA静脉溶栓治疗,对照组采用rt-PA静脉溶栓治疗,比较两组临床症状评分、凝血状态、脑血流动力学及血清标志物水平。结果:治疗后研究组美国国立卫生院卒中量表(NIHSS)评分低于对照组,卒中影响量表(SIS)、Berg平衡量表(BBS)评分高于对照组(P<0.05);治疗后研究组凝固时间(KT)、凝血反应时间(RT)高于对照组,最大振幅(MA)、凝固角(α)低于对照组(P<0.05);治疗后研究组平均脑部动脉血流速度(Vm)、收缩期血流速度(Vs)、舒张末期血流速度(Vd)高于对照组,阻力指数(RI)低于对照组(P<0.05);治疗后研究组胶质纤维酸性蛋白(GFAP)、血管性血友病因子(vWF)、血管细胞黏附分子(VCAM-1)水平低于对照组(P<0.05)。结论:化瘀通脉汤联合rt-PA静脉溶栓治疗气虚血瘀证脑卒中可以降低患者神经功能损伤,改善日常活动能力,改善凝血状态,提高脑血流灌注,降低神经炎症。

扩心方治疗急性心肌梗死后患者心室重构的临床观察

目的观察扩心方联合西医标准治疗对急性心肌梗死后患者心室重构的临床疗效。方法纳入100例患者随机分为对照组和观察组,每组50例,对照组给予西医标准治疗,观察组在此基础上加用扩心方,疗程12周。检测治疗前后临床疗效、心超指标(LVEF,LVEDD,LVESD,IVS,LVPWT),血清NT-proBNP,ST-2,Galectin-3,MMP-9,PICP,IL-6,VEGF以及MLHFQ评分、Lee氏心衰评分、主要心血管不良事件、安全性指标变化。结果观察组总有效率高于对照组(P<0.05)。治疗后,观察组EF、LVEDD、LVESD改善优于对照组(P<0.05),血清NT-proBNP,ST2,Galectin-3,MMP-9,PICP,IL-6下降均优于对照组(P<0.05),血清VEGF增加优于对照组(P<0.05),两组患者均未发现明显不良反应。结论扩心方联合西医标准治疗可安全有效地缓解心肌梗死后患者临床症状,改善心室重构。

脑安滴丸联合常规治疗对气虚血瘀证脑梗死恢复期患者的临床疗效

目的探讨脑安滴丸联合常规治疗对气虚血瘀证脑梗死恢复期患者的临床疗效。方法80例患者随机分为对照组和观察组,每组40例,对照组给予常规治疗,观察组在对照组基础上加用脑安滴丸,疗程4周。检测临床疗效、中医证候评分、炎症因子(TNF-α、IL-6、IL-4)、VEGF、NSE、BDNF、脑部血流动力学指标(RI、Vm、PI)、SS-QOL评分、NIHSS评分、BI评分变化。结果观察组总有效率高于对照组(P<0.05)。治疗后,2组中医证候评分、炎症因子、NSE、RI、PI、NIHSS评分降低(P<0.05),VEGF、BDNF、Vm、SS-QOL评分、BI评分升高(P<0.05),以观察组更明显(P<0.05)。结论脑安滴丸联合常规治疗可改善气虚血瘀证脑梗死恢复期患者神经功能缺损、脑部血流动力学、生活质量、日常生活自理能力,调节血清TNF-α、IL-6、IL-4、VEGF、NSE、BDNF水平,降低中医证候评分,提高临床疗效。

通天口服液治疗脑梗死恢复期瘀血阻络挟风证的安全性与有效性

目的:观察通天口服液治疗脑梗死恢复期瘀血阻络挟风证的安全性与有效性。方法:选取2020年1月—2022年1月上海市第六人民医院治疗的脑梗死恢复期瘀血阻络挟风证病人185例,采用随机数字表法将病人分为观察组和对照组。对照组予以常规治疗,观察组在常规治疗基础上予以通天口服液治疗,两组疗程均为8周。记录两组研究期间不良反应发生情况。疗程结束后,比较两组临床疗效、安全性及治疗前后两组血清神经营养因子(NTF)、神经元特异性烯醇化酶(NSE)、髓鞘碱性蛋白(MBP)、神经生长因子(NGF)、脑源性神经营养因子(BDNF)及超敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)炎性因子水平。结果:治疗后,观察组总有效率为92.86%,对照组为74.23%,两组比较差异有统计学意义(P<0.05)。治疗后,观察组血清NTF、BDNF及NGF水平较治疗前升高,血清NSE、MBP水平较治疗前下降,且观察组治疗后血清NTF、BDNF及NGF水平高于对照组,血清NSE、MBP水平低于对照组,差异均有统计学意义(P<0.05或P<0.01)。治疗后,观察组血清炎性因子hs-CRP、IL-1β、IL-6及TNF-α水平均较治疗前下降,且观察组治疗后血清hs-CRP、IL-1β、IL-6及TNF-α水平低于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率为3.06%,对照组为2.06%,两组比较差异无统计学意义(P>0.05)。结论:通天口服液可改善脑梗死恢复期瘀血阻络挟风证病人症状,显著提高临床疗效,且安全性较高,其作用机制可能与升高血清神经因子NTF、BDNF及NGF水平,降低血清神经因子NSE、MBP水平及血清炎性因子hs-CRP、IL-1β、IL-6、TNF-α水平有关。

针刺颅底五穴联合化痰通络汤治疗后循环梗死性眩晕的临床研究

目的:探讨针刺颅底五穴联合化痰通络汤对痰瘀阻络型急性后循环梗死性眩晕(PCIV)的临床疗效。方法:选取2022年10月—2023年10月在深圳市宝安区中医院诊断为后循环梗死性眩晕(脑梗死急性期)、中医辨证为痰瘀阻络证的病人114例作为研究对象,按照随机数字表法分为观察组(54例)和对照组(60例),对照组给予口服化痰通络汤治疗,观察组在对照组基础上针刺颅底五穴治疗,两组均予神经内科基础治疗及对症支持治疗,疗程14 d。比较两组治疗前后的中医证候积分、眩晕障碍量表(DHI)积分、脑血流动力学指标、低密度脂蛋白胆固醇(LDL-C)、同型半胱氨酸(Hcy)、临床疗效。结果:与治疗前比较,两组治疗后中医证候积分、DHI积分、LDL-C、Hcy均显著下降(P<0.05);双侧椎动脉(VA)、基底动脉(BA)平均血流速度均显著升高(P<0.05)。与对照组比较,观察组治疗后中医证候积分显著降低(P<0.05),临床治疗总有效率升高(P<0.05)。与对照组比较,观察组治疗后VA、BA平均血流速度显著升高(P<0.05);DHI积分、LDL-C、Hcy显著下降(P<0.05)。结论:针刺颅底五穴联合化痰通络汤治疗痰瘀阻络型急性后循环梗死性眩晕的临床应用效果显著,可提高病人日常生活能力及生活质量,改善脑血流状态,调节脂代谢,保护脑血管。